mAIbe and LenioBio Form Strategic Partnership to Accelerate AI-Driven Monoclonal Antibody Discovery
核心洞察
mAIbe (搜索) and LenioBio (搜索) announced a strategic collaboration combining AI-driven antibody design with cell-free protein expression technology to enhance therapeutic antibody discovery.
The partnership integrates mAIbe (搜索)'s physics-informed generative AI platform with LenioBio (搜索)'s ALiCE cell-free expression system to accelerate the design-build-test cycle.
The collaboration aims to increase efficiency and throughput of early validation while enabling faster iteration between computational predictions and experimental results.
mAIbe (搜索), a biotechnology company focused on AI-guided monoclonal antibody design, and LenioBio (搜索), a biotechnology company pioneering cell-free protein expression, announced a new strategic collaboration aimed at accelerating the discovery and experimental validation of next-generation monoclonal antibodies (搜索).
Complementary Technologies Drive Innovation
The partnership combines mAIbe (搜索)'s AI-driven platform for antibody design and optimization with LenioBio (搜索)'s cell-free expression technology, bringing together two complementary strengths to significantly enhance the design-build-test cycle. LenioBio's ultrafast, scalable expression system enables rapid production of complex antibodies, providing high-quality experimental data that feeds directly into mAIbe's AI models.
Joint Objectives and Capabilities
Through this integrated approach, the two teams will jointly accelerate functional testing of AI-generated antibody candidates, increase the efficiency and throughput of early validation, and enable faster iteration between computational predictions and experimental results.
The collaboration represents a convergence of cutting-edge technologies, with mAIbe (搜索)'s platform combining physics-informed generative AI and synthetic biology to develop precise, cost-effective antibodies targeting viral and bacterial pathogens (搜索). LenioBio (搜索)'s ALiCE platform enables rapid discovery, development, and scalable production of proteins beyond the limits of living cells.
Setting New Industry Standards
Together, mAIbe (搜索) and LenioBio (搜索) aim to set a new standard for speed, flexibility, and data-driven innovation in therapeutic antibody discovery by closing the lab-in-loop gap. This partnership addresses a critical bottleneck in antibody development by seamlessly integrating computational design with experimental validation.
Company Backgrounds
LenioBio (搜索) GmbH, founded in Germany in 2016, is headquartered in Düsseldorf with R&D and manufacturing facilities in Aachen. The company pioneered cell-free protein expression with its ALiCE platform.
mAIbe (搜索), based in Rome, Italy, operates at the convergence of artificial intelligence and life sciences to accelerate the development of accessible, next-generation immunotherapies. The company's platform focuses on developing antibodies targeting viral and bacterial pathogens (搜索) through AI-guided design approaches.